NYSE:CVS

CVS Health Corp (CVS)

95.93
+1.11 (1.17%)
as of Jun 5, 2026, 8:00:00 pm Market Open.
247 watching
0
PAST TOP PICK
(A Top Pick May 03/22, Down 28%)

Has great expectations for company, will continue to hold.
Trading ~8x earnings. 
Owns many legacy assets and brands.
~10,000 storefronts for strong retail business.
Good long term hold. 
Cash flow juggernaut with excellent margins. 
Good management team.

BUY

Makes a lot of sense for a long-term hold. Beat numbers. Poor guidance going forward. Health business, rather than just a drugstore, but this creates volatility in earnings sometimes. Focus on integrated strategy is the right approach.

DON'T BUY

It is trying to become vertically integrated in managed care, health insurance, doctors networks. It is attempting to be a turn-around story so wait until it executes on its strategy of becoming a conglomerate. There are other companies that are best in class already

PAST TOP PICK
(A Top Pick May 05/22, Down 27%)

Acquisitions have hampered stock price. Targets keep getting pushed our further. Lowered guidance. May be support levels around this price. Trades at 8x forward earnings, well below its historical 12.5x PE. Growth remains elusive. Dividend's great at 3.5%.

STRONG BUY

He bought more CVS. Not a bad earnings report, but have extra costs coming from the Oak Street  and Signify purchases. They've been growing earnings for the past 5 years at 10% annually. Are paying down debt. Trades at 8x earnings and pays a 3.3% dividend. Great long-term hold.

TOP PICK

Likes diversified health care like this, including health insurance and pharmacy. They bought Oak Street for $9.5 billion and 10% of their market cap. Not profitable yet, but CVS will integrate Oak Street and raise profits. They just hired from Humana for Aetna a new and smart president. Sells at a good valuation and pays a 3.5% dividend. Weakness partially comes from not passing on higher costs to customers. He's held CVS for a while and has gone round-trip.

(Analysts’ price target is $107.13)

DON'T BUY

Its retail exposure is impacted with more prescriptions being filled online. He prefers UNH. 

BUY

Excellent entry point at current share price.
Recent M&A not supported by the market.
Believes long term prospects good for healthcare.
Looming recession not a concern.
Good long term investment. 
Vertically integrated healthcare company.

COMMENT

He owns a lot of health stocks. CVS has been a problem child all year, down 23%, but it's bottoming now. The market is figuring out their Oak Street buy and Signify and how that will be accretive.

BUY

It's starting to come back and is bottoming. The CEO is doing a great job and pays a 3.2% dividend yield and trades at 9x PE.

DON'T BUY

They do drug retail in the U.S. Also have a PBM business and health insurance. Their strategy is to broaden their offerings by buying companies. She owned this a few years ago. Trades at a low PE, but all those purchases and PBM is limited by outside forces to limit health costs, so this is an overhang.

BUY

He doesn't know why it is so low. The FMV is good and earnings look good as well. Hold if you have it and if the Book Value reaches his target of $60 to $65 buy more. Has great potential.

BUY ON WEAKNESS

It's lagged 20% and is bottoming as they try to absorb Signify and Oak Street. Going forward, there is upside.

HOLD

Shares have fallen due to rotation out of healthcare into energy & growth 
~3% yield attractive to investors.
Too defensive for investors at this stage in the cycle.
Value for long term investors.
Better options for investors who want capital gains. 

PAST TOP PICK
(A Top Pick May 04/22, Down 25%)

Disappointing. Two good acquisitions pending. Insurance division is losing market share. Covid gains downstream have waned. Growth lull, but almost a record low at 8x earnings. Huge addressable market. Will get mojo back.

Showing 31 to 45 of 409 entries